key: cord-0712885-xt25u5ah authors: Nascimento, Rebeca Barros; Araujo, Nara Santos; Silva, Jamerson Carvalho; Xavier, Flávia Caló Aquino title: Oral manifestations of multisystemic inflammatory syndrome in children (MIS‐C) and Kawasaki disease associated to COVID‐19: A systematic review date: 2021-11-18 journal: Spec Care Dentist DOI: 10.1111/scd.12669 sha: 9c70bdc13bcd13eb3d28de121c54a9780b11975f doc_id: 712885 cord_uid: xt25u5ah AIMS: Multisystemic inflammatory syndrome in children (MIS‐C) is a condition noted in some children asymptomatic but positive to Sars‐cov‐2 antibody and it presents clinical and laboratory changes similar to Kawasaki disease (KD). Oral changes have also been observed. This systematic review evaluated oral manifestations detected in children with MIS‐C and KD associated to COVID‐19. METHODS AND RESULTS: This work was registered at PROSPERO (#CRD42020225909), following PRISMA guidelines. A comprehensive research was conducted in MEDLINE, Web of Science, EMBASE, LILACS, Scopus, and Grey Literature through August 2021, based on original research evaluating children diagnosed with MIS‐C or KD related to COVID‐19. Two authors independently screened all retrieved references. Twenty five selected studies evaluated 624 children, mean age 8.78 years. The assessment of the risk of bias (ROB) showed that most of them presented low ROB. Oral manifestations were erythematous mucous membrane, oral ulcers lesions, dry, swollen and cracked lips, and strawberry tongue. CONCLUSION: MIS‐C and KD share the same oral manifestations and their identification may lead to an early diagnosis. The role of COVID-19 in the pathogenesis of MIS-C is unclear. 3 Normally, this syndrome occurs late to COVID-19 infection and, in general, patients present positive IgG and IgM but negative PCR to Sars-Cov-2. 4, 5 Commonly they are treated as they have KD with IV immunoglobulin (IVIg). 5 Center of Disease Control and Prevention (CDC) defined criteria for MIS-C: serious illness leading to hospitalization, less than 21 years, fever (body temperature, >38.0 • C) or report of subjective fever lasting at least 24 hours, laboratory evidence of inflammation, multisystem organ involvement (involving at least two systems), and laboratory confirmed SARS-CoV-2 infection (positive SARS-CoV-2 real-time reverse-transcriptase polymerase chain reaction [RT-PCR] or antibody test during hospitalization) or an epidemiologic link to a person with COVID-19. 6 In this context, patients present 4-5 days of fever, rash, conjunctivitis, oral mucosal changes, gastrointestinal symptoms (vomiting and diarrhea), and laboratories changes as neutrophilia, lymphopenia, elevated serum of inflammatory markers (CRP), and ferritin concentrations, that are evidence of significant inflammation. 1, 2 Patients can also present hypercoagulable state and pancarditis, an inflammation of pericardium, myocardium and endocardium, and others complex problems like dysfunction of the left ventricular, hyperechoic coronary arteries. More complex complications have been reported in children with this syndrome, such as systemic thrombosis and coronary artery aneurysms. Despite the low rate, some cases evolve to death. 2 Initially, these children were diagnosed as incomplete KD because they met the criteria set by the American Heart Association in 2017. 3, 5, 7 Oral changes are noted in children with KD, and they have also been observed as a manifestation of MIS-C such as dry, erythematous or cracked lips, erythema of the oropharyngeal mucosa, strawberry tongue (prominent lingual papillae), and others less frequent oral symptoms. 4, 5, 7, 8 Oral changes were reported in isolated studies that observed systemic manifestations in patients with PMIS-TS 4, 5, 7 ; however, there are few studies summarizing these oral manifestations; and there is still a question about whether these lesions are due to coronavirus infection or secondary manifestations resulting from the patient's systemic condition. Thus, the early diagnosis of oral manifestations of COVID-19 to better profile the role of pediatric dentists should be emphasized, considering the need for support, pain control, and quality of life. In addition, the dentist's relevance as part of the multidisciplinary team in supporting critical of these patients should be highlighted. In this context, the aim of this study is to perform a systematic review (SR) for evaluating oral manifestations associated to MIS-C and KD related to emergent COVID-19 in children. An SR was written and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA Statement) checklist recommendations and was registered on PROSPERO (International prospective register of systematic reviews; protocol number #CRD42020225909). 9 This SR was developed aiming to identify and characterize oral manifestations in children with a diagnosis of either MIS-C or KD associated to COVID-19. The acronym PECO (Population/context, Exposition, Control and Outcomes) was used to formulate the focused question of this Integrative Review: "What are the oral manifestations of Multisystemic Inflammatory Syndrome in Children (MIS-C) and Kawasaki disease associated to COVID-19?". According to these criteria: P, children who developed multisystemic inflammatory syndrome or KD; E, the exposition was the COVID-19; C, control was not applied; O, oral manifestations. Eligible studies included original research studies published in peer-reviewed journals, mainly focusing on epidemiology, burden, prevalence, risk factors, or incidence of oral manifestations of MIS-C or KD. All primary studies, including case reports, that positively identified children defined as age less than 18 years with potential diagnosis of MIS-C in addition to a positive SARS-coV-2 PCR test result, SARS-coV-2 serum antibody assay, or epidemiologic link to person who tested positive were included. Only reports published or accepted after December 2019 were eligible, as MIS-C or KD prior to this date is not related to SARS-coV-2. Exclusion criteria were studies that reported patients with negative SARS-coV-2 PCR or negative SARS-coV-2 serum antibody, literature or SR papers, letter to the editor, monographs, thesis, interviews, conference papers, and studies that did not describe in detail the study population. In addition, analysis in patients with any systemic disease was not considered. Article screening was performed independently by two reviewers (R.B.N. and N.S.A.). Disagreement was resolved by discussion, and the measurement of interreview agreement (Kappa statistic) was calculated. Study selection was performed in a two-phase process: first, the reviewers independently applied the eligibility criteria for titles and abstracts of all identified references, whereas, in phase-2, the same eligibility criteria were applied to the full-text studies. Care was taken to ensure that any studies reported more than once were not counted twice; if a study had been more than one, the most complete reporting of the relevant population was considered for inclusion. The same reviewers independently assessed the methodological quality of the selected studies according to their level of evidence, as proposed by the Joanna Briggs Institute Methodological Index, 10 with some adjustments, according to the study design proposed in each article selected. Doubts and discrepancies between the reviewers were also discussed. In the final analysis, studies were categorized as "high ROB (Risk of Bias)" when the study achieved up to a 49% "yes" score; "Moderate ROB" when the study reached 50%-69% "yes" score; and "low ROB" when the study reached over 70% "yes" score. Data extracted from the articles were classified as quantitative or qualitative by one of the reviewers (N.S.A.) and then checked by another (R.B.N.). The data were collected from the papers selected, and then organized in structured tables. Demographics including age, location and design of study, oral manifestations, laboratory investigations, and treatments provided were recorded for each study. The case reports were combined into one data set and the number of patients, in each study, with treatment were recorded. A total of 361 potentially relevant references were identified in the search; 37 were considered duplicated and were therefore removed. No manuscripts were identified through grey literature. After titles and abstracts screening, 37 studies remained. Reading these study texts resulted in exclusion of 19 more studies due to: (3) study design as letter to the editor, 3,11,12 (5) review article, [13] [14] [15] [16] [17] (8) because they did not evaluate or report or have the oral manifestations, 18, 19 (2) due to patients being older than 18-year-old, 20,21 and (1) the patients had underlying diseases. 22 A manual search for articles identified eight more studies. Overall, 25 studies were selected for the analysis (Tables 1 and 2 ). Details of the search strategy are presented in Figure 1 . 4, 5, 7, 8, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] The Kappa inter-investigator agreement for articles that were selected (K ≥ 0.85) from showed an acceptable level of agreement. The main characteristics of the included studies are presented in Table 1 . Fifteen studies were case report (n = 23 children), 4, 5, 7, 8, 23, [30] [31] [32] 35, 36, [38] [39] [40] [41] [42] two was a case series (n = 68), 27, 43 five were prevalence studies (n = 277), 25, 28, 29, 33, 37 two were cohort studies (n = 26), 24, 26 and one was a case-control study (MIS-C group = 44; KD = 7; control = 181). 34 The bias risk assessment showed that among the included papers, 23 presented as a good-quality study according to JBI criteria whereas two presented moderated RoB (Table 3) . Overall, the main biases identified were (1) small sample size, (2) did not assess clear the presence of confounding factors and/or did not report a strategy to deal with them, (3) did not provide sufficient information about diagnosis criteria, and (4) unclear answers regarding the post-intervention clinical condition. reports of children assisted in pediatric centers that have been diagnosed to MIS-C or KD in most of cases based on CDC and AHA criteria, although some authors based on UK or World Health Organization (WHO) criteria. COVID-19 was diagnosed by the positive RT-PCR test to the virus or by the identification of anti-Sars-Cov-2 antibodies (IgG and IgM) and, in some cases, due to exposure to a COVID-19 positive person. Hospitalized children due to MIS-C or KD were treated by infusion of IVIgs associated or not with the use of corticosteroids. In general, remission of the symptoms occurred after IVIg infusion but in some cases a second infusion was necessary. Few deaths have been reported. Most of patients were recovered. Oral manifestations were noticed as one of the most common symptoms of MIS-C. These oral changes are similar in both KD and MIS-C reported in patients with KD and MIS-C covered lips, tongue, and other mucous membranes. Authors identified erythematous, dry and/or cracked lips, erythematous mucous membranes and sometimes ulcers as aphthous stomatitis, and erythematous tongue, sometimes presenting strawberry shape. MIS-C is an emergent disease identified during COVID-19 pandemic. KD and MIS-C share clinical and laboratory features that made many authors initially diagnose as "Incomplete Kawasaki disease" because they met the criteria set by the American Heart Association in 2017. These criteria include (1) fever lasting more than 5 days, Study Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 % A s h r a fe ta l . exclusion of other diseases. Coronary artery abnormalities including dilation of coronary arteries and aneurysms may also occur. Evidence of myocarditis is commonly seen but patients rarely present with hemodynamic instability and shock. 7, 44 The emerging number of children presenting a multisystem inflammatory syndrome led the CDC to define criteria for its diagnosis, which were used by most authors as a basis for the diagnosis of this disease. CDCs criteria are: (1) age < 21 years presenting with fever (≥38.0 • C for ≥24 hours, or report of subjective fever lasting ≥24 hours), laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (≥ 2) organ involvement;(2) no alternative plausible diagnoses; and (3) positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms. 6 The diagnose of COVID-19 was mainly reported by positive identification of virus on RT-PCR test and by the identification of anti-Sars-Cov-2 antibodies (IgG and IgM). In some patients, tests were negative but diagnosis of COVID-19 was considered when the patient had exposure to a positive person, which is recommended by CDC. Oral manifestations are often noted in patients with KD, 45, 46 and they have also been observed in patients with MIS-C. In the present study, cases of studies that did not present oral involvement were excluded according to eligibility criteria. Since, during the selection of articles, most of the published cases presented these oral changes. In these cases, oral manifestations frequently noted in MIS-C patients do not differ from those identified on KD patients. In both disease, children may present erythematous mucous membranes and tongue with or without lesions like ulcers (aphthous stomatitis), lips may be erythematous, swollen, dry, and/or cracked. Usually, these symptoms are accompanied by burning and/or pain and reduced oral intake. 5, 8, 23, 27, 35 In general, oral manifestations were observed as one of the first symptoms of the disease. In some cases, due to the delay in the diagnosis with consequent worsening of the clinical condition, the disease evolved to a more severe condition, requiring intubation. The identification of oral manifestations associated to other clinical signs and a history of positivity for the COVID-19 virus can help in early diagnosis and prevent sequelae and deaths from this disease. The treatment of oral conditions has not been reported in any case presented in the articles analyzed in this current review. However, signs and symptoms of MIS-C or KD usually regressed after treatment with IVIg associated to corticosteroids and/or aspirin, so probably there was remission of oral manifestations, although the authors did not clearly report this information. Papers published before COVID-19 pandemic showed that oral manifestations of KD also regressed after systemic treatment with IVIg. 45, 46 In addition, it was noted that no research has been developing focusing on oral cavity manifestations, and recently one letter to the editor has been published summarizing oral changes reported by authors that evaluate systemic condition. 47 Most of the cases analyzed in this review were case reports, which is due to the emergent COVID-19 pandemic, and despite the speed of publication, it was noted that the analyzed studies presented low to moderated RoB. However, at the moment of their publication, some of these papers had not yet ended the treatment and had no outcome or did not make the outcome clear, which probably happened after the article has been published. 4, 8, 36, 37 In this context, it is important to reinforce the role of dental professionals in the early detection of the oral manifestations and referral for further investigation. The rapid detection of COVID-19 is crucial to control outbreaks; only using early identification of oral manifestations and consequent early diagnosis, it is possibly effective and rapid isolation of cases and the appropriate contact tracing. Thus, it should be highlighted that other studies and reports about this topic are surely required. MIS-C and KD may have high mortality and morbidity rate if not treated early, and hence an early diagnosis and treatment are important because children are at increased risk of deterioration. The oral findings, mainly erythematous mucous membranes, lesions like ulcers, dry and cracked lips, and strawberry tongue, are a characteristic feature of both diseases and can occur earlier than systemic manifestations. Many cases might first report to the dental clinician so dentists should always remain alert in handling patients presenting those oral manifestations and to associate to COVID-19. The responsibility of Rebeca Barros Nascimento was to conceive the idea, to conduct the systematic review, and to write -original draft. The responsibility of Nara Santos Araujo was to conceive the idea, to conduct the systematic review, and to write -original draft. The responsibility of Jamerson Carvalho Silva was to conduct the systematic review and to write -original draft. The responsibility of Flávia Caló Aquino Xavier was to orient and supervision the work and to write -review and editing. All authors made substantial contributions to acquisition of data, drafting the article, revising it critically, and have approved the final version to be submitted. These authors contributed equally. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declared that there is no conflict of interest. No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article. Hyperinflammatory shock in children during COVID-19 pandemic Paediatric inflammatory multisystem syndrome temporally-associated with SARS-CoV-2 infection: an overview Dermatological manifestation of pediatrics multisystem inflammatory syndrome associated with COVID-19 in a 3-year-old girl COVID-19 inflammatory syndrome with clinical features resembling kawasaki disease SARS-CoV-2-Induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children Centers for Disease Control and Prevention Emergency Preparedness and Response: Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease Three cases of pediatric multisystem inflammatory syndrome associated with COVID-19 due to SARS-CoV-2 Pediatric inflammatory multisystem syndrome temporally associated with COVID-19: a spectrum of diseases with many names Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach Oral ulceration as presenting feature of paediatric inflammatory multisystem syndrome associated with COVID-19 Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics Recommendations for the initial management of multisystem inflammatory syndrome temporally related to COVID-19, in children and adolescents Consensus on treatment of multisystemic inflammatory syndrome associated with COVID-19 Potential link between SARS-CoV-2 and Kawasaki disease: importance of dentists for the diagnosis Enfermedad de Kawasaki y su posible Asociación con el Nuevo SARS-CoV-2 (Covid-19) Toxic shocklike syndrome and COVID-19: a case report of multisystem inflammatory syndrome in children (MIS-C) Multisystem inflammatory syndrome in children (MIS-C) in an adolescent that developed coronary aneurysms: a case report and review of the literature Oral complications of ICU patients with COVID-19: case-series and review of two hundred ten cases Oral manifestations of COVID-2019-related multisystem inflammatory syndrome in children: a review of 47 pediatric patients SARS-CoV-2 infection in infants under 1 year of age in Wuhan City COVID-19 and Kawasaki disease: novel virus and novel case Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 Multisystem inflammatory syndrome in children rose and fell with the first wave of the COVID-19 pandemic in France Defining Kawasaki disease and pediatric inflammatory multisystem syndrometemporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey Paediatric inflammatory multisystem syndrome temporally associated with COVID-19: a new virus and a new case presentation Multisystem inflammatory syndrome (MIS-C) in an adolescent Nigerian girl with COVID-19: a call for vigilance in Africa Multisystem inflammatory syndrome in children Kawasaki disease-like features in 10 pediatric COVID-19 cases: a retrospective study Discriminating multisystem inflammatory syndrome in children requiring treatment from common febrile conditions in outpatient settings Multisystem inflammatory syndrome in children temporally related to COVID-19: a case report from Saudi Arabia Kawasaki disease features and myocarditis in a patient with COVID-19 Multisystem inflammatory syndrome in U.S. children and adolescents A novel pediatric multisystem inflammatory syndrome during the covid-19 pandemic Case report: inflammation and endothelial injury profiling of COVID-19 pediatric multisystem inflammatory syndrome (MIS-C). Front Pediatr Multisystem inflammatory syndrome in children in February 2020 and implications of genomic sequencing for SARS-CoV-2 Children with Kawasaki disease or Kawasaki-like syndrome (MIS-C/PIMS) at the time of COVID-19: are they all the same? Case series and literature review Kawasaki shock syndrome and Covid-19 Multisystemic inflammatory syndrome in children associated with COVID-19: a single center experience in Turkey Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association Recurrent lip swelling as a late presentation of Kawasaki disease: case report and review of literature Recurrent Kawasaki disease presenting to dentists Pediatric multisystem inflammatory syndrome temporally associated with SARS-COV-2: oral manifestations and implications Additional supporting information may be found in the online version of the article at the publisher's website.